decisionhealth Newsletters, Part B News - 2023 Issue 2 (February)
CMS unveils inflation drug pricing changes, with a Part B wrinkle coming soon
Subscribe or sign in to view the full article.
Article Overview
This article covers recent CMS and HHS activity related to Medicare drug pricing under the Inflation Reduction Act. It explains the broad categories of policy changes, including rebate guidance for Medicare Part B and Part D drugs, proposed CMS Innovation Center models, and an upcoming Part B payment/coinsurance adjustment that may affect some practices that dispense drugs. The article is relevant for providers, billing and reimbursement staff, pharmacy and practice administrators, and others tracking Medicare drug policy changes.
Why This Topic Matters
These updates affect how Medicare drug pricing policy is being implemented, what kinds of future payment and access models CMS is testing, and when certain Part B billing and patient cost-sharing changes may begin to appear in practice. It helps stakeholders anticipate administrative and reimbursement changes without replacing the detailed guidance in the full article.
Article Sections
-
Inflation Reduction Act and Medicare drug-pricing background
Introduces the broader policy context for CMS and HHS drug-pricing activity and summarizes the categories of Medicare drug changes discussed in the article.
-
Monitor the February drug changes
Reviews the February CMS guidance and comment request, along with the timing and general framework of the rebate-related policy updates.
-
No flak expected
Discusses industry reaction and commentary on the proposed CMS innovation models and their potential implications for drug access and payment policy.
-
Watch for coinsurance change
Highlights the near-term Part B payment and coinsurance update described by CMS and its relevance for practices that dispense affected drugs.
-
Resources
Lists source documents and reference materials cited by the article.
What You Will Learn
- The main CMS and HHS drug-pricing developments tied to the Inflation Reduction Act
- The general purpose of CMS rebate guidance for Medicare drug prices
- The types of Innovation Center models CMS announced for further testing
- The nature of the upcoming Part B coinsurance/payment update for affected drugs
- Where CMS and Federal Register source materials are referenced for follow-up
Who Should Read This
- Medical coders
- Billing and reimbursement staff
- Practice managers
- Pharmacy administrators
- Compliance teams
- Medicare policy analysts
- Health care administrators
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com